Investors

Event Calendar

 

Upcoming Events

Q2 2022 Financial Results week of 01 August 2022

Read more


    Q3 2022 Financial Results week of 07 November 2022

    Read more


      Year End 2022 Financial Results week of 06 March 2023

      Read more


        Past Events

        ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

        December 10, 2021

        Read more

        ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo

        October 23, 2021

        Read more

        ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

        September 20, 2021

        Read more
        1 2 3 4 5 30

        General Meetings

        ObsEva Annual General Meeting 2018

        May 9, 2018

        Read more

        ObsEva Extraordinary General Meeting 2018

        January 28, 2018

        Read more
        1 2 3 4
         
         

        Sign up for news

         
         

          * Type:


          InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












          Read our privacy policy here.


           

          Are you sure you want to leave ObsEva.com?

          We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

          Continue to link

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue